Peptidomimetic α-Acyloxymethylketone Warheads with Six-Membered Lactam P1 Glutamine Mimic: SARS-CoV-2 3CL Protease Inhibition, Coronavirus Antiviral Activity, and in Vitro Biological Stability

Bing Bai,Alexandr Belovodskiy,Mostofa Hena,Appan Srinivas Kandadai,Michael A. Joyce,Holly A. Saffran,Justin A. Shields,Muhammad Bashir Khan,Elena Arutyunova,Jimmy Lu,Sardeev K. Bajwa,Darren Hockman,Conrad Fischer,Tess Lamer,Wayne Vuong,Marco J. van Belkum,Zhengxian Gu,Fusen Lin,Yanhua Du,Jia Xu,Mohammad Rahim,Howard S. Young,John C. Vederas,D. Lorne Tyrrell,M. Joanne Lemieux,James A. Nieman

DOI: https://doi.org/10.1021/acs.jmedchem.1c00616

IF: 8.039

2021-07-09

Journal of Medicinal Chemistry

Abstract:Recurring coronavirus outbreaks, such as the current COVID-19 pandemic, establish a necessity to develop direct-acting antivirals that can be readily administered and are active against a broad spectrum of coronaviruses. Described in this Article are novel α-acyloxymethylketone warhead peptidomimetic compounds with a six-membered lactam glutamine mimic in P1. Compounds with potent SARS-CoV-2 3CL protease and in vitro viral replication inhibition were identified with low cytotoxicity and good plasma and glutathione stability. Compounds 15e, 15h, and 15l displayed selectivity for SARS-CoV-2 3CL protease over CatB and CatS and superior in vitro SARS-CoV-2 antiviral replication inhibition compared with the reported peptidomimetic inhibitors with other warheads. The cocrystallization of 15l with SARS-CoV-2 3CL protease confirmed the formation of a covalent adduct. α-Acyloxymethylketone compounds also exhibited antiviral activity against an alphacoronavirus and non-SARS betacoronavirus strains with similar potency and a better selectivity index than remdesivir. These findings demonstrate the potential of the substituted heteroaromatic and aliphatic α-acyloxymethylketone warheads as coronavirus inhibitors, and the described results provide a basis for further optimization.The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.1c00616?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.1c00616</a>.Glutathione stability studies (Table S1); protease, antiviral, and cytotoxicity graphs for 15l; slopes of kobs versus [I] for 15a, 15e, 15f, 15h, and 15l (Table S2 and Charts S1 and S2); electron density for SARS-CoV-2 3CLP – 15l active sites (Figure S1); SARS-CoV-2 3CLP – 15l ligand plot (Figure S2) and crystallographic data (Table S3); and 1H NMR, 19F NMR, and HPLC for select compounds (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.1c00616/suppl_file/jm1c00616_si_001.pdf">PDF</a>)Molecular formula strings for all compounds with biological data (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.1c00616/suppl_file/jm1c00616_si_002.csv">CSV</a>)This article has not yet been cited by other publications.

chemistry, medicinal

What problem does this paper attempt to address?

Peptidomimetic α-Acyloxymethylketone Warheads with Six-Membered Lactam P1 Glutamine Mimic: SARS-CoV-2 3CL Protease Inhibition, Coronavirus Antiviral Activity, and in Vitro Biological Stability

REVISITING THE SARS-COV-2 MAIN PROTEASE: A 2023 IN SILICO ODYSSEY IN SEARCH OF POTENTIAL INHIBITORS

Novel Alkynylamide-Based Nonpeptidic Allosteric Inhibitors for SARS-CoV-2 3-Chymotrypsin-like Protease

Design, Synthesis, and Biological Evaluation of Peptidomimetic Aldehydes as Broad-Spectrum Inhibitors against Enterovirus and SARS-CoV-2

Design, Synthesis, and Unprecedented Interactions of Covalent Dipeptide-Based Inhibitors of SARS-CoV-2 Main Protease and its Variants Displaying Potent Antiviral Activity

Azapeptides with unique covalent warheads as SARS-CoV-2 main protease inhibitors

Synthesis and biological evaluation of novel Peptidomimetic inhibitors of the coronavirus 3C-like protease

Discovery of Peptidomimetic Spiropyrrolidine Derivatives As Novel 3clpro Inhibitors Against SARS-CoV-2

A Quick Route to Multiple Highly Potent SARS‐CoV‐2 Main Protease Inhibitors**

Broad-spectrum coronavirus 3C-like protease peptidomimetic inhibitors effectively block SARS-CoV-2 replication in cells: Design, synthesis, biological evaluation, and X-ray structure determination

Exploiting high-energy hydration sites for the discovery of potent peptide aldehyde inhibitors of the SARS-CoV-2 main protease with cellular antiviral activity

Potent and selective covalent inhibition of the papain-like protease from SARS-CoV-2

Structure-guided design of direct-acting antivirals that exploit the gem-dimethyl effect and potently inhibit 3CL proteases of severe acute respiratory syndrome Coronavirus-2 (SARS-CoV-2) and middle east respiratory syndrome coronavirus (MERS-CoV)

Peptidyl nitroalkene inhibitors of main protease rationalized by computational and crystallographic investigations as antivirals against SARS-CoV-2

Discovery and structure-activity relationship studies of novel α-ketoamide derivatives targeting the SARS-CoV-2 main protease

Discovery of Di- and Trihaloacetamides as Covalent SARS-CoV-2 Main Protease Inhibitors with High Target Specificity

Discovery of the potent covalent inhibitor with an acrylate warhead for SARS-CoV-2 3CL protease

Expedited Approach toward the Rational Design of Noncovalent SARS-CoV-2 Main Protease Inhibitors

Invention of MK-7845, a SARS-CoV-2 3CL Protease Inhibitor Employing a Novel Difluorinated Glutamine Mimic

Discovery of CMX990: A Potent SARS-CoV-2 3CL Protease Inhibitor Bearing a Novel Warhead

A Speedy Route to Multiple Highly Potent SARS-CoV-2 Main Protease Inhibitors